Search research articles
Contact Us
Filters
Showing results (51-60 of 176) with videos related to
Page
of 18
Sort By:
Journal of Critical Care
|
August 9, 2023
Outcome and factors associated with mortality in patients receiving urgent chemotherapy in the ICU: A retrospective study
Jean Bernard, Charles-Hervé Vacheron, Nicolas Vantard, et al.
American Journal of Cancer Research
|
June 7, 2021
HMGA1 induces EZH2 overexpression in human B-cell lymphomas
Marco De Martino, Pedro Nicolau-Neto, Luis Felipe Ribeiro Pinto, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 24, 2017
Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study
Alexandre Morel, Josette Brière, Laurence Lamant, et al.
Histopathology
|
April 25, 2013
Immunoarchitectural patterns in splenic marginal zone lymphoma: correlations with chromosomal aberrations, IGHV mutations, and survival. A study of 76 cases
Alexandra Traverse-Glehen, Emmanuel Bachy, Lucile Baseggio, et al.
Nature Medicine
|
April 25, 2025
Author Correction: T cell malignancies after CAR T cell therapy in the DESCAR-T registry
Remy Dulery, Vincent Guiraud, Sylvain Choquet, et al.
Nature Medicine
|
January 8, 2025
T cell malignancies after CAR T cell therapy in the DESCAR-T registry
Remy Dulery, Vincent Guiraud, Sylvain Choquet, et al.
British Journal of Haematology
|
March 25, 2021
Real-life targeted next-generation sequencing for lymphoma diagnosis over 1 year from the French Lymphoma Network
Côme Bommier, Claire Mauduit, Juliette Fontaine, et al.
Leukemia & Lymphoma
|
November 15, 2023
Retrospective multicenter comparative study of the efficacy and safety between R-DHAC and R-DHAOx in diffuse large B-cell lymphoma or transformed follicular or marginal zone B lymphoma into aggressive lymphoma, as a second-line treatment
Ludovic Fouillet, Elisabeth Daguenet, Emmanuelle Tavernier, et al.
Haematologica
|
December 26, 2015
Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients
Mathilde Lamarque, Céline Bossard, Adrien Contejean, et al.
Bulletin Du Cancer
|
January 11, 2021
[Eligibility of patients for CAR T-cell: Expert opinion-based collaborative work by the SFGM-TC]
David Beauvais, Emmanuel Bachy, André Baruchel, et al.
Page
of 18
Search research articles
Search
Showing results (51-60 of 176) with videos related to
Sort By:
Page
of 18
Journal of Critical Care
|
August 9, 2023
Outcome and factors associated with mortality in patients receiving urgent chemotherapy in the ICU: A retrospective study
Jean Bernard, Charles-Hervé Vacheron, Nicolas Vantard, et al.
American Journal of Cancer Research
|
June 7, 2021
HMGA1 induces EZH2 overexpression in human B-cell lymphomas
Marco De Martino, Pedro Nicolau-Neto, Luis Felipe Ribeiro Pinto, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 24, 2017
Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study
Alexandre Morel, Josette Brière, Laurence Lamant, et al.
Histopathology
|
April 25, 2013
Immunoarchitectural patterns in splenic marginal zone lymphoma: correlations with chromosomal aberrations, IGHV mutations, and survival. A study of 76 cases
Alexandra Traverse-Glehen, Emmanuel Bachy, Lucile Baseggio, et al.
Nature Medicine
|
April 25, 2025
Author Correction: T cell malignancies after CAR T cell therapy in the DESCAR-T registry
Remy Dulery, Vincent Guiraud, Sylvain Choquet, et al.
Nature Medicine
|
January 8, 2025
T cell malignancies after CAR T cell therapy in the DESCAR-T registry
Remy Dulery, Vincent Guiraud, Sylvain Choquet, et al.
British Journal of Haematology
|
March 25, 2021
Real-life targeted next-generation sequencing for lymphoma diagnosis over 1 year from the French Lymphoma Network
Côme Bommier, Claire Mauduit, Juliette Fontaine, et al.
Leukemia & Lymphoma
|
November 15, 2023
Retrospective multicenter comparative study of the efficacy and safety between R-DHAC and R-DHAOx in diffuse large B-cell lymphoma or transformed follicular or marginal zone B lymphoma into aggressive lymphoma, as a second-line treatment
Ludovic Fouillet, Elisabeth Daguenet, Emmanuelle Tavernier, et al.
Haematologica
|
December 26, 2015
Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients
Mathilde Lamarque, Céline Bossard, Adrien Contejean, et al.
Bulletin Du Cancer
|
January 11, 2021
[Eligibility of patients for CAR T-cell: Expert opinion-based collaborative work by the SFGM-TC]
David Beauvais, Emmanuel Bachy, André Baruchel, et al.
Page
of 18